ALB and hepatocellular carcinoma: Studies conducted by Ikeda et al. [28] and O’Suilleabhain et al. [29] confirmed that a low pre-treatment serum ALB level is an independent factor which predicts worse OS in HCC patients treated with transarterial embolization (TAE) or transarterial chemoembolization (TACE).